

Edward A Stadtmauer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4280021/publications.pdf>

Version: 2024-02-01

63
papers

3,189
citations

394421

19
h-index

161849

54
g-index

65
all docs

65
docs citations

65
times ranked

5732
citing authors

#	ARTICLE	IF	CITATIONS
1	CRISPR-engineered T cells in patients with refractory cancer. <i>Science</i> , 2020, 367, .	12.6	872
2	NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. <i>Nature Medicine</i> , 2015, 21, 914-921.	30.7	728
3	Carfilzomib-Associated Cardiovascular Adverse Events. <i>JAMA Oncology</i> , 2018, 4, e174519.	7.1	196
4	Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. <i>Lancet Haematology</i> , 2015, 2, e408-e416.	4.6	158
5	A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. <i>Blood</i> , 2014, 124, 2921-2929.	1.4	145
6	Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. <i>JCI Insight</i> , 2018, 3, .	5.0	140
7	T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. <i>Blood Advances</i> , 2019, 3, 2812-2815.	5.2	133
8	Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 3320-3328.	1.3	67
9	Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma. <i>Blood Advances</i> , 2019, 3, 2022-2034.	5.2	58
10	Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2019, 68, 2003-2009.	5.8	54
11	Early Donor Chimerism Levels Predict Relapse and Survival after Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1758-1766.	2.0	52
12	High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning. <i>Journal of Clinical Oncology</i> , 2015, 33, 2392-2398.	1.6	52
13	Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. <i>Blood Advances</i> , 2021, 5, 3748-3759.	5.2	43
14	Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1187-1195.	2.0	38
15	Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract. <i>Bone Marrow Transplantation</i> , 2019, 54, 212-217.	2.4	34
16	Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis. <i>American Journal of Hematology</i> , 2017, 92, 879-884.	4.1	28
17	Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas. <i>American Journal of Hematology</i> , 2016, 91, 672-676.	4.1	27
18	Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 515-521.	2.0	24

#	ARTICLE	IF	CITATIONS
19	Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2398-2407.	2.0	21
20	Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy. <i>Cancer</i> , 2020, 126, 1837-1855.	4.1	20
21	Risk of invasive fungal infections in patients with <scp>high-risk MDS</scp> and <scp>AML</scp> receiving hypomethylating agents. <i>American Journal of Hematology</i> , 2020, 95, 792-798.	4.1	20
22	Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma. <i>Blood</i> , 2018, 132, 1886-1886.	1.4	19
23	Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma. <i>Haematologica</i> , 2017, 102, e261-e265.	3.5	17
24	Cellular and vaccine immunotherapy for multiple myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 521-527.	2.5	16
25	Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e7-e15.	2.0	16
26	Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1999, 16, 279-288.	1.1	15
27	The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 6580-6590.	7.0	15
28	Fluoroquinolone Prophylaxis Is Highly Effective for the Prevention of Central Line-Associated Bloodstream Infections in Autologous Stem Cell Transplant Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1004-1010.	2.0	13
29	Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 410-422.	1.2	13
30	PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells. <i>Blood</i> , 2018, 132, 1973-1973.	1.4	13
31	Nutrition-Related Outcomes for Autologous Stem Cell Transplantation Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e393-e398.	0.4	12
32	Femtomolar SARS-CoV-2 Antigen Detection Using the Microbubbling Digital Assay with Smartphone Readout Enables Antigen Burden Quantitation and Tracking. <i>Clinical Chemistry</i> , 2021, 68, 230-239.	3.2	11
33	Lenalidomide in Combination with Dexamethasone Is More Effective Than Dexamethasone at First Relapse in Relapsed Multiple Myeloma.. <i>Blood</i> , 2006, 108, 3552-3552.	1.4	10
34	R-CHOP or R-HyperCVAD With or Without Autologous Stem Cell Transplantation for Older Patients With Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 92-97.	0.4	9
35	Identifying Professional Education Gaps and Barriers in Multiple Myeloma Patient Care: Findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 356-369.	0.4	7
36	Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment. <i>American Journal of Hematology</i> , 2016, 91, 453-460.	4.1	7

#	ARTICLE	IF	CITATIONS
37	Real World Survival Outcomes of CPX-351 Versus Venetoclax and Azacitidine for Initial Therapy in Adult Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 795-795.	1.4	7
38	Bâ€cell maturation antigen chimeric antigen receptor Tâ€cell reâ€expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitorâ€based combination therapy. <i>British Journal of Haematology</i> , 2021, 193, 851-855.	2.5	6
39	Tailoring initial treatment for newly diagnosed, transplantation-eligible multiple myeloma. <i>Oncology</i> , 2010, 24, 7-13.	0.5	6
40	A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. <i>Clinical Advances in Hematology and Oncology</i> , 2007, 5, 7-19, quiz 21-2.	0.3	5
41	Effect of malnutrition-driven nutritional support protocol on clinical outcomes in autologous stem cell transplantation patients. <i>Supportive Care in Cancer</i> , 2021, 29, 997-1003.	2.2	4
42	Survival Analysis from the CALGB Study of Lenalidomide Maintenance Therapy in Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation Adjusted for Crossover (Alliance) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 53		
43	Immunoglobulin Free Light Chain (FLC) and Heavy Chain/Light Chain (HLC) Assays â€ Comparison with Electrophoretic Responses in Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 2877-2877.	1.4	4
44	A Phase I Study of Hydroxychloroquine with Infusional Cyclophosphamide, Pulse Dexamethasone and Rapamycin in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 3449-3449.	1.4	4
45	Unrelated donors are associated with improved relapseâ€free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2016, 91, 883-887.	4.1	3
46	Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI. <i>American Journal of Hematology</i> , 2016, 91, 426-429.	4.1	3
47	Melphalan desensitization following immediate hypersensitivity in a patient undergoing conditioning for autologous hematopoietic cell transplantation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 555-556.	3.8	3
48	Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. <i>Transfusion</i> , 2020, 60, 1867-1872.	1.6	3
49	CAR T cell therapy for multiple myeloma: What have we learned?. <i>Leukemia</i> , 2022, 36, 1481-1484.	7.2	3
50	The Impact of Rituximab Resistance on Overall Survival Rate in Low-Grade Follicular Lymphoma. <i>Blood</i> , 2008, 112, 3783-3783.	1.4	2
51	A Phase 1 Trial of Fluphenazine HCl (Fz), a Serotonin Antagonist, in Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2008, 112, 5188-5188.	1.4	2
52	Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 524-529.	1.9	1
53	Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1203-1208.	2.0	1
54	Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 431.e1-431.e8.	1.2	1

#	ARTICLE	IF	CITATIONS
55	Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing. Blood, 2018, 132, 2134-2134.	1.4	1
56	Overall Survival Remains Important in Trials of Early-Line Multiple Myeloma Therapy. Journal of Clinical Oncology, 2021, , JCO2101754.	1.6	0
57	Timing between Rituximab and 90Y-Ibritumomab Tiuxetan in Pts with Non-Hodgkinâ€™s Lymphoma Does Not Affect Clinical Outcomes.. Blood, 2006, 108, 4735-4735.	1.4	0
58	A Prospective Clinical Trial of a Novel Epstein-Barr Virus (EBV) PCR Panel in Patients with EBV Associated Malignancies.. Blood, 2007, 110, 2628-2628.	1.4	0
59	Initial Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase I Clinical Trial of Systemic C-MYB Antisense Oligodeoxynucleotide in Subjects with Refractory Hematologic Malignancies. Blood, 2008, 112, 4033-4033.	1.4	0
60	Clinical Trial of a Multitarget EBV PCR Panel In Patients with EBV Positive Malignancies: Correlation of Peripheral Blood EBV Viral Load with Disease Activity. Blood, 2010, 116, 5079-5079.	1.4	0
61	A Study of Outcomes of Diffuse Large B Cell Lymphoma in the Elderly. Blood, 2011, 118, 4950-4950.	1.4	0
62	Time from Relapse to Donor Leukocyte Infusion in Allogeneic Stem Cell Transplantation Patients Is Longer for Recipients of Unrelated DLI Compared to Matched Sibling DLI, with Similar Incidence of Graft Versus Host Disease (GVHD) and Survival. Blood, 2014, 124, 3946-3946.	1.4	0
63	Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplant. Journal of Oncology Pharmacy Practice, 2022, , 107815522210807.	0.9	0